About adma biologics inc - ADMA
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.
ADMA At a Glance
ADMA Biologics, Inc.
465 State Route 17 South
Ramsey, New Jersey 07446
| Phone | 1-201-478-5552 | Revenue | 510.17M | |
| Industry | Biotechnology | Net Income | 146.93M | |
| Sector | Health Technology | 2025 Sales Growth | 19.631% | |
| Fiscal Year-end | 12 / 2026 | Employees | 647 | |
| View SEC Filings |
ADMA Valuation
| P/E Current | 15.183 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 30.40 |
| Price to Sales Ratio | 8.756 |
| Price to Book Ratio | 9.09 |
| Price to Cash Flow Ratio | 88.64 |
| Enterprise Value to EBITDA | 22.348 |
| Enterprise Value to Sales | 8.741 |
| Total Debt to Enterprise Value | 0.018 |
ADMA Efficiency
| Revenue/Employee | 788,520.866 |
| Income Per Employee | 227,094.281 |
| Receivables Turnover | 3.22 |
| Total Asset Turnover | 0.902 |
ADMA Liquidity
| Current Ratio | 6.708 |
| Quick Ratio | 3.739 |
| Cash Ratio | 1.26 |
ADMA Profitability
| Gross Margin | 57.357 |
| Operating Margin | 37.525 |
| Pretax Margin | 35.803 |
| Net Margin | 28.80 |
| Return on Assets | 25.966 |
| Return on Equity | 35.562 |
| Return on Total Capital | 26.369 |
| Return on Invested Capital | 29.888 |
ADMA Capital Structure
| Total Debt to Total Equity | 16.736 |
| Total Debt to Total Capital | 14.337 |
| Total Debt to Total Assets | 12.613 |
| Long-Term Debt to Equity | 15.917 |
| Long-Term Debt to Total Capital | 13.635 |